Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia

Wiener Klinische Wochenschrift

Volumn 118, Issue 19-20, 2006, Pages 595-600

  Hofer, Harald ^a   Gurguta, Calin ^a   Bergholz, Ulrike ^a   Steindl Munda, Petra ^a   Ferenci, Peter ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Hepatitis C virus; Interferon therapy; Liver cirrhosis; Thrombocytopenia

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; FEVER; HEPATITIS C; HOSPITALIZATION; HUMAN; LIVER DISEASE; SIDE EFFECT; THROMBOCYTOPENIA; WEIGHT REDUCTION;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; THROMBOCYTOPENIA;

EID: 33846280515     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-006-0704-0     Document Type: Article

References (27)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK. Shiffman M, Reindollar R, et al (2001) Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomized trial. Lancet 358: 958-965
2. Fried MW, Shiffman ML, Reddy RK, Smith C, Marinos G, Goncales F, et al (2002) Peginterferon alfa-2a plus ribavirin: for chronic hepatitis C virus infection. N Engl J Med 347: 975-982
3. Cooksley WGE, Dudley FJ, Watson K (1997) Treatment of cirrhotic hepatitis C virus patients with daily doses of interferon-2a. J Viral Hepat 4 [Suppl 2]: 75-78
4. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR (2002) A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 8: 350-355
5. Davis GL, Albright JE, Cook SF, Rosenberg DM (2003) Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9: 331-338
6. Moreno Planas JM, Rubio Gonzalez E, Boullosa Grana E, Fernandez Ruiz M, Jimenez Garrido M, Lucena de la Poza JL, et al (2005) Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation. Transplant Proc 37: 2207-2208
7. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al (2000) Peginterferon alpha 2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343: 1673-1680
8. Moriyama M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Shioda A, et al (2005) Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy. Liver Int 25: 85-90
9. Hino K, Okita K (2004) Interferon therapy as chemoprevention of hepatocarcinogenesis in patients with chronic hepatitis C. J Antimicrob Chemother 53: 19-22
10. Moreno A, Barcena R, Blazquez J, Quereda C, Gil-Grande L, Sanchez J, et al (2004) Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirin. Antivir Ther 9: 1027-1030
11. Kercher KW, Carbonell AM, Heniford BT, Matthews BD, Cunningham DM, Reindollar RW (2004) Laparoscopic splenectomy reverses thrombocytopenia in patients with hepatitis C cirrhosis and portal hypertension. J Gastrointest Surg 8: 120-126
12. Homoncik H, Ferlitsch A, Formann E, Jilma B, Gangl A, Panzer S, et al (2005) Short- and long-term effects of therapy with interferon-α and pegylated interferon-α on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. Alimentary Pharmac Ther 21: 49-55
13. Peck-Radosavljevic M, Wichlas M, Pidlich J, Sims P, Meng G, Zacherl J, et al (1998) Thrombopoetin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 28: 1424-1429
14. Wang Q, Miyakawa Y, Fox N, Kaushansky K (2000) Interferon-alpha directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 15: 2093-2099
15. Everson GT, Trotter JF, Kugelmas M (2004) Impaired virological response in patients with avanced liver disease due to chronic hepatitis C is independently linked to severity of disease: result from the HALT C trial. Hepatology 40: 180A
16. Everson GT (2005) Should we treat patients with chronic hepatitis C on the waiting list? J Hepatol 42: 456-462
17. Puoti M, Babudieri S, Rezza G, Viale P, Antonini MG, Maida I, et al (2004) Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther 9: 627-630
18. Stauber RE, Hofer H, Hackl F, Schutze K, Datz C, Hegenbarth K, et al (2004) Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. Wien Klin Wochenschr 116: 530-535
19. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al (2005) Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42: 255-262
20. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31: 864-871
21. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, et al (2005) Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 5: 118-124
22. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al (2005) Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 41: 289-298
23. Schmid M, Kreil A, Jessner W, Homoncik M, Datz C, Gangl A, et al (2005) Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 54: 1014-1020
24. Thomas RMBJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH (2003) Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 9: 905-915
25. Forns X, Serrano T, Feliu A, Suarez F, de la Mat, Garcia-Valdecasas, et al (2003) Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 39: 389-396
26. Sanchez Turrion V, Cuervas-Mons Martinez V (2005) Effectiveness of pegylated interferon and ribavirin in patients with liver HCV cirrhosis. Transplant Proc 37: 1482-1483
27. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al (2003) Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis after liver transplantation: A randomized study. Gastroenterology 124: 642-650